Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 6, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of share ownership changes rather than a financial performance report.
Material Changes
The filing details a change in the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan ("the Plan").
- Date of Movement: December 2, 2005
- Previous Holdings: 18,416,461 ADRs
- New Holdings: 18,474,542 ADRs
- Average Price: $50.47
Two directors, Dr. J P Garnier and Dr. T Yamada, are noted as potentially interested in the shares held in the fund in the same capacity as other employees or former employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the specific transaction described above.
Key Facts for Investor Verification
- Verify the impact of the 58,081 ADR increase in the US Retirement Savings Plan on overall insider ownership percentages.
- Confirm the specific roles of Dr. J P Garnier and Dr. T Yamada to understand their potential interest in the fund.
- Note that this filing does not contain financial performance data for the period; refer to Form 20-F for comprehensive financial results.